To explore how urologists manage prostate cancer (PCa) screening and treatment in patients undergoing endoscopic enucleation of the prostate (EEP).
A team of experts in EEP collaboratively formulated the survey questions through an interactive process. The survey opened in January 2024 and closed in February 2024.
102 urologists responded, revealing that most use PSA and digital rectal examination for screening, with high PSA and abnormal DRE prompting prostate MRI. 75% perform pre-EEP biopsies. For incidental low-grade PCa, active surveillance is preferred. For intermediate-grade PCa, most use PSA and MRI for workup, often choosing active surveillance if post-EEP biopsies are negative. There's no consensus on abnormal post-operative PSA thresholds.
While urologists are aware of PCa management in EEP candidates, future work should focus on developing optimal post-EEP screening protocols.
Prostate cancer and prostatic diseases. 2024 Oct 21 [Epub ahead of print]
Alessandro Uleri, Jean Nicolas Cornu, Benjamin Pradere, Thomas R W Herrmann, Vincent Misrai, Morgan Roupret, Cosimo De Nunzio, Hashim Hashim, Guillaume Ploussard, Michael Baboudjian
Department of Urology, APHM, North Academic Hospital, Marseille, France. ., Department of Urology, Charles-Nicolle Hospital, University of Rouen Normandy, Rouen, France., Department of Urology, La Croix du Sud Hôpital, Quint Fonsegrives, France., Department of Urology, Cantonal Hospital Thurgau AG, Fraunfeld, Switzerland., Department of Urology, Clinique Pasteur, Toulouse, France., Sorbonne University, GRC 5 Predictive Onco-Uro, AP-HP, Urology, Pitie-Salpetriere Hospital, Paris, France., Department of Urology, Sapienza University of Rome, Rome, Italy., Bristol Urological Institute, Southmead Hospital, Bristol, UK., Department of Urology, APHM, North Academic Hospital, Marseille, France.